NEW YORK--(BUSINESS WIRE)--DellaCamera Capital Management, LLC, today delivered a letter to the Board of Directors of Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) stating its ongoing belief that the Company’s stock is significantly undervalued and that it is encouraged by the Company’s present commitment to enhance shareholder value. DellaCamera beneficially owns in excess of 7% of Enzon’s common stock.
